《The Ophthalmic Pharmaceutical Market Outlook to .ppt》由会员分享，可在线阅读，更多相关《The Ophthalmic Pharmaceutical Market Outlook to .ppt（7页珍藏版）》请在三一办公上搜索。
1、The Ophthalmic Pharmaceutical Market Outlook to 2016,Competitive landscape,pipeline analysis,and growth opportunities,BI00042-019September 2011118 pages,11 figures,20 tablesMarkets&Therapies,US5EUJapan,AllerganNovartisMerck&Co.PfizerSanten PharmaceuticalISTA Pharmaceuticals,GlaucomaDry eye syndromeA
2、ge-related macular degenerationDiabetic retinopathyDiabetic macular edema,Xalatan/Xalacom declining but will maintain the top spot to 2016,Patents on most of the leading brands in the ophthalmic market have either already expired or are expected to do to by 2012Xalatan,Lumigan and Alphagan will all
3、decline rapidly in the face of patent expiries to 2016Saflutan sales are forecast to grow strongly,exceeding$400m by 2016,Retinal diseases are the fastest growing segment,The ophthalmic market will grow steadily at a CAGR of 4.6%,reaching$21.1bn in 2016Glaucoma is the largest market segment with 201
4、0 sales of$5.5bn,accounting for 35%of the marketDespite increasing prevalence,the glaucoma market will grow slowly to 2016Artificial tears and anti-infectives will show static sales over the forecast period,Ch 2.Glaucoma Sec:Epidemiology;Market landscape;Forecast of key products,Source:Company repor
5、ts,Business Insights,Aging population and obesity to drive retinal diseases market,The prevalence of age related macular degeneration(AMD)will increase from 26.5m to 29.2m by 2016There are 109 products in development for AMD,the greatest number of any ophthalmic indicationWorldwide,the diabetes popu
6、lation is growing at an average annual growth rate of 2.3%to 2030 which will steadily drive diabetic retinopathy prevalenceRoche/Novartis blockbuster monoclonal antibody,Lucentis leads the market with sales of$2.9bn in 2010Avastin is increasingly used off-label in the treatment of wet AMD due to an
7、attractive price point against Lucentis;Avastin is in Phase III development for wet AMDAvastin is also under development for diabetic macula edemaEyelea and lluvein are the other key pipeline products for wet AMD,Ch.4 Retinal diseases.Sec:Forecast epidemiology;Key marketed products,Research and deve
8、lopment,Restasis still dominates the prescription dry eye syndrome market,The prevalence of dry eye syndrome is forecast to rise from 48.2m to approach 50m in 2016The disease has a prevalence of 17%in Japan compared with 3-6%for the other major marketsRestasis generated 2010 sales of$621m at a Y-o-Y
9、 growth of 18.7%Allergan aims to extend Restasis life cycle,by developing new version,Restasis X,which contains a different preservative.Rabamipide(Otsuka)has been filed in Japan and is under Phase II development in the USDiquas was approved in Japan in 2010,however US development of the drug failed
10、 in Phase III trialsResolvyx/Celtic Therapeutics RX-10045 and ISTAs Remura are the main pipeline products in development for dry eye,Ch.3.Dry eye syndrome.Sec:Key marketed products;Research and development,Novartis remains the leading player in the ophthalmology market,Novartis total acquisition of
11、Alcon has made it the leading ophthalmic player by a large marginNovartis has 5 ophthalmic products in Phase III trials,and has 3 regulatory filings pendingSales of Merck and Co.s Trusopt and Cosopt are declining rapidly following patent expiriesPfizers presence in the segment is in decline as patents expire on the Xalatan franchise,Ch.6 Key company profiles.Sec:Novartis;Allergan;Merck Pfiizer,The Diabetes Market Outlook to 2016,BI00042-006,BI00022-059,BI00022-023,Opportunities in Emerging Pharma Markets,The OTC Pharmaceutical Market in Emerging Countries,
